Miller on Oncology

+ Add to Email Alerts
- Match Programs vs the NFL Draft: Where Would You End Up?
- Considering the True Costs of Clinical Trials
2
- FES PET for ER-Positive Breast Cancer: How Can It Help?
- NATALEE, PHERGain Show Promise in Breast Cancer at ASCO
- Want to Thank Trial Participants? Provide Crossover
- SABCS 2022 ER+ Breast Cancer Data: SERDs, Pregnancy, and New Targets
- SABCS 2022 Deescalating DCIS: Experts Discuss New Data From SABCS
5
- Covering for a Colleague: My Treatment Recommendation or Theirs?
22
- ASCO 2022 'Real-World' Data: Watchword or Accurate Description?
2
- ASCO 2022 'It's an ADC World': New Breast Cancer Data From ASCO 2022
1
- What Explains 'Sobering' Variations in Breast Cancer Care?
- Managing a Loved One's Finances: 'Do You Have a Magic Book?'
- ASCO 2021 Real-World Breast Cancer Tx Fall Far Short of Trial Outcomes
1
- Adjuvant IO Fails in BRCA+ Breast Cancer Patient; Now What?
1
- We Need to Level With Our Patients About Tumor Sequencing
- Looking for a Good Read? Two End-of-Summer Book Recommendations
2
- ASCO 2021 For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
1
- ASCO 2021 Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
- ASCO 2021 ASCO 2021: Breast Cancer Sessions Not to Miss
- The Power of Independent Data Monitoring Committees Is Diminishing
- Single-Cell Sequencing Upends Breast Cancer Assumptions
3
- Margetuximab for HER2+ Metastatic Breast Cancer Falls Short
- CONTESSA: Oral Taxane Meets Primary Endpoint
4
- RxPONDER: Chemo 'No Longer a Mandate' for Some With Breast Cancer
1
- ESMO 2020 Opposing Trial Results on CDK Inhibitors Means Good Science
1
- ESMO 2020 Innate Immune Response Produces 'Phenomenal' Breast Cancer Control
3
- ESMO 2020 For Immunotherapy in TNBC, Nab-paclitaxel Is a Must
1
- Surprising Results From the PALLAS Trial
4
- In Breast Cancer, Is Chemobrain Really 'Endocrine Brain'?
2
- Three Practice-Informing Breast Cancer Trials From ASCO 2020
2
- ASCO Plenary Highlights Importance of Publicly Funded Research
- Let's Not 'Waste' COVID-19: Opportunities for Improvement
- De-escalation of Cancer Treatment: When Is Less Really More?
- As Home Genetic Tests Flood Market, Are Physicians Being Left Behind?
1
- Three Questions Can Help Quantify Health Disparities
- Early ImmunoRx Results in TNBC 'Put Us in a Difficult Position'
2
- 'Huge Year' for HER2+ Breast Cancer: Incorporating New Treatments
- Remembering Bernie: An Early Champion in Breast Cancer
4
- Is the 'Value' Movement Affecting Everyday Oncology Practice?
1
- Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals
- 'Pendulum Has Swung Too Far' in Opioid Limits for Cancer Pain
25
- Breast Cancer Genetic Testing Guidelines 'Simply Are Not Effective'
9
- Let's Put Breast Implant Lymphoma Risk in Context
15
- Randomized Data (Finally) on Partial Breast Irradiation
- #MeToo Era Presents Complex Questions for Oncology
2
- Hudis on CancerLinQ: Goal Is Real-Time 'Accident Avoidance System'
- Interpreting the 'Messy Early Days' of Immunotherapy in Breast Cancer
1
- Kathy Miller on IMpassion130: New Standard? Not Yet
3
- 'No Excuse' for Undisclosed COI, but Perhaps a Simple Solution
9
- Diagnosing Inflammatory Breast Cancer: Can We Get on the Same Page?
4
- Are Oncology Pathways 'Achieving the Goals We Promised'?
- Clinical Pathways: Many Potential Benefits but 'More Work to Do'
- TAILORx Provides 'Clear Answer' for ER+ Breast Cancer
1
- Long-Awaited TAILORx Results 'Will Impact Your Practice'
- 'False Hope' Over Immunotherapy? The Media's Misguided Effects
11
- 'Cultural Change' in DCIS
7
- Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers
- Will Immunotherapy Be a PANACEA for Breast Cancer?
3
- For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
- Does Breast Cancer Risk REACT to Celecoxib?
- Hot Topics (and Hot Chilis): SABCS 2017
2
- Two 'P' Words Top List of Hot Topics in Breast Cancer
- Should High-Risk Breast Cancer Patients Go Back on an AI?
4
- Vitamin D: A New Intervention for Melanoma?
13
- Will Real-World 'Bias' of Big Data Improve Cancer Care?
1
- Trastuzumab Biosimilar: An Understudy Waits in the Wings
- Can Guidelines Spur Political Action in MBC?
4
- Breast Cancer: Big Questions Answered?
4
- Bread Comas and Other Not-to-Miss Chicago Treats
- On Mother's Day, Let's Think About Our Patients
2
- Big Data vs Breast Cancer Trials Raises Big Issues
1
- Ovarian Suppression in BC: Right or Wrong, Depending
5
- Benefits of Additional Chemo in Residual Breast Cancer
3
- Out-of-Pocket Can Mean Cancer Meds Are Out
- Not to Diss Denosumab, but More Data Needed in Breast Cancer
- From Bedside to Bench: A New Direction in Breast Cancer Research
- Breast Cancer and Pregnancy: POSITIVE Study Welcome
5
- Pembrolizumab Shows Durable Responses in TNBC
1
- Jury Still Out on Anthracyclines in HER2+ Breast Cancer
1
- SABCS Promises 'Seismic Tremors' for Breast Cancer
1
- Oncologist Asks for Your Second Opinion
53
- Money Talks: Solution to Soaring Costs of Cancer Drugs?
8
- SHAVE a Big Plus in Breast Cancer
11
- Is Patient’s 'Right to Try' Law All Wrong?
21
- Pertuzumab and the Curious Case of Accelerated Registration
1
- Sorting Therapy Options in Locoregional Breast Cancer
- Weight Loss WINS in Breast Cancer
2
- SABCS Wrap-up: Will TNT Quietly Change Practice?
- HER2+ Therapy: Getting Less Toxic All the Time
1
- SOFT Yields Hard Data on Hormone Therapy
1
- TNT Refines Platinum Use in TNBC
- SOFT Trial Landing at SABCS
1
- BRCA Screening: Good Sense or Gattaca Rising?
15
- Will Clinical Pathways Go the Way of the Dinosaur?
6
- 'Got It Right': Guidelines for HER2-Negative Breast Cancer
4
- Is Fast MRI Better Than Mammography?
22
- ASCO President on the Triumph of the Open Mind
6
- ASCO Presidents Survey 50 Years of Oncology
3
- Oncology and ASCO: A Family Affair
1
- Results Flat in ALTTO Breast Cancer Trial
3